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Objective: In England, 27,500 children are referred annually to hospital with constipation. An 
objective measure of whole gut transit time (WGTT) could aid management. The current standard 
WGTT assessment, the X-ray radiopaque marker (ROM) test, gives poor definition of colonic anatomy 
and the radiation dose required is undesirable in children. Our objective was to develop an alternative 
MRI WGTT measure to the X-ray ROM test and to demonstrate its initial feasibility in pediatric 
constipation. 
Methods: With the Nottingham Young Person’s Advisory Group (YPAG) we developed a small 
(8mm×4mm), inert polypropylene capsule shell filled with MRI-visible fat emulsion. The capsule can 
be imaged using MRI fat and water in-phase and out of phase imaging. Sixteen patients with 
constipation and 19 healthy participants aged 7-18 years old were recruited. Following a common 
ROM protocol, the participants swallowed 24 mini-capsules each day for 3 days and were imaged on 
day 4 and 7 using MRI. The number of successful studies (feasibility) and WGTT were assessed. 
Participants’ EQ-VAS were also collected and compared between the day before the taking the first 
set of mini-capsules to the day after the last MRI study day. 
Results: The mini-capsules were imaged successfully in the colon of all participants. The WGTT was 
78±35 hours (mean±SD) for patients, and 36±16 hours, P < 0.0001 for healthy controls. Carrying out 
the procedures did not change the EQ-VAS scores before and after the procedures.  
Conclusions: MAGIC (Magnetic Resonance Imaging in Pediatric Constipation) was a first-in-child 
feasibility study of a new medical device to measure WGTT in pediatric constipation using MRI. The 
study showed that the new method is feasible and was well tolerated.  
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What Is Known 
• Current methods for assessing whole gut transit time (WGTT) include the traditional 
abdominal X-ray and radiopaque markers (ROM).   
• X-ray ROM methods expose children and young people ionising radiation in the range 0.03-
0.11 mSv. 
• X-ray ROMs produce two-dimensional radiographs where the bowel and location of the 
ROM markers may be difficult to distinguish.  
 
What Is New 
• We developed a new, magnetic resonance imaging (MRI) visible mini-capsule, specifically 
aimed at children and young adults.  
• This first-in-child feasibility study showed that WGTT can be measured in pediatric 







Functional constipation in childhood is common, with estimated prevalence of 14% (1-5). The 
diagnosis is based on symptom  and is defined according to the Rome IV diagnostic criteria (6-8) 
which for a child over 4 years of age must include two or more of the following (7): 1) two or fewer 
defecations in the toilet/week. 2) At least one episode of fecal incontinence/week. 3) History of 
retentive posturing or excessive volitional stool retention. 4) History of painful or hard bowel 
movements. 5) Presence of a large fecal mass in the rectum. 6) History of large diameter stools that 
can obstruct the toilet. Managing this condition can be challenging. Whole gut transit time (WGTT) 
imaging studies have long been used (9) as an objective measure which can assist in stratifying patients 
and directing management. Gut transit studies have been reported to help characterise normal transit 
(10), anorectal retention (outlet obstruction) (11), non-retentive faecal incontinence (12) and slow 
transit constipation (11, 13) and can be particularly useful when medical history and/or physical 
examination is unreliable (13).  
Current methods include both gamma scintigraphy and X-ray radiopaque markers (ROMs). Both 
techniques involve exposure to ionising radiations, which is undesirable in young persons (14, 15). 
The effective exposure dose provided can vary considerably depending on isotopes and techniques. 
Radiolabelled meals in gamma scintigraphy can provide between 0.1 mSv (16, 17) up to 1-4 mSv (18) 
and X-ray can provide between 0.03 and 0.11 mSv (19). Scintigraphy uses radiolabelled tracers to 
determine transit time. Lack of standardisation (20) and  limited availability make its use problematic. 
In the conventional Metcalf ROMs method (21), the patients ingest a number of small, inert plastic 
pellets on 3 consecutive days after which a series of abdominal radiographs are taken to assess the 
location of the markers inside the gastrointestinal tract (GI), thereby determining WGTT. The ROMs 
method is more widely available than scintigraphy. However, it is often difficult to determine the 
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location of the radiopaque markers accurately on an X-ray film due to the tortuous structure of the 
large bowel and the limitations of two-dimensional X-ray projection imaging. 
Magnetic resonance imaging (MRI) has already revolutionised diagnostics in many fields and is 
recently coming of age for the assessment of functional GI diseases (22). WGTT has been recently 
measured using adult-sized, MRI visible capsules in health and constipation but the size of the capsules 
make them unsuitable for children (23-26). 
This study aimed therefore at developing an MRI alternative to the X-ray ROMs, specifically targeted 





The Rome IV criteria was used to identify patients with childhood functional constipation following a 
referral either from primary or secondary care into a specialist clinic at Nottingham University 
Hospitals NHS Trust were recruited between April 2018 and June 2019 (Fig. 1). By the time they 
reached the specialist clinic, these patients were at various stages of treatment and there was no 
expectation that they would change treatment plan whilst participating as this was a feasibility study 
of the new methodology. During the same period healthy participants, who had normal bowel habit 
and did not suffer from constipation or diarrhoea, were recruited by advertisement from the local 
community. The CONSORT Diagram (27) is shown in Fig. 1. All participants were aged between 7 
and 18 years old. A minimum age of 7 was selected as at this age participants are more likely to have 
had some experience of swallowing tablets. In participants younger that that age compliance with MRI 
procedures could also have been lower and motion artifacts could have been more frequent, precluding 
analysis. Participants with existing antegrade colonic enema (ACE) procedure were excluded as well 
as patients with a history of GI surgery that could affect GI function, including colectomy or small 
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bowel resection. Exclusion criteria included inability to lie flat and relatively still for less than 5 
minutes and typical MRI scanning contraindications such as presence of metallic implants, 
pacemakers, history of metallic foreign body in eyes. This study was approved by the UK National 
Research Ethics Committee (17/WM/0049), by the Medicines and Healthcare products Regulatory 
Agency (MHRA) (CI/2017/0054) and registered on Clinicaltrials.gov (NCT03564249). 
Study Design 
This was an open label, feasibility, case-control study in a University setting. The intervention in this 
study mirrored a common X-ray ROM protocol (21). The rationale behind it is to load the 
gastrointestinal tract with repeated daily doses of a plurality of markers to achieve a steady state and 
then image the location of the markers in the gastrointestinal tract at predetermined time points (9). 
Many variants of this type of protocol have been proposed and we have chosen the one involving 3 
daily doses of 24 markers each, which was also used for example for the common Sitzmarks®  ROMs 
product (9, 28). 
More specifically: participants were asked to swallow 24 mini-capsules each morning at home for 3 
consecutive days (72 mini-capsules in total), by either mixing the mini-capsules in yoghurt, or 
swallowing with water or fruit juice. The participants underwent a short MRI scan on day 4. If mini-
capsules were still seen in the bowel, a second short MRI scan was performed on Day 7. If mini-
capsules were still seen in the bowel, they underwent a third MRI scan around day 26-28. This last 
scan was not part of the WGTT test but performed to collect data on possible retention of mini-
capsules. EQ-VAS (visual analogue scale) questionnaire data (29) was collected at baseline and each 
day of the study (day 0, before they started taking the mini-capsules to day 8). EQ-5D-Y data (30) was 
also collected at baseline. The questionnaire evaluates health-related life domains such as mobility, 
self-care and pain. The lowest scores set possible for the EQ-5D-Y is 1,1,1,1,1 indicating no issues 
with any of the 5 domains. Scores higher than 1 in one or more domains indicate loss of QoL. All 
questionnaires used with permission. In addition to the Consort Diagram at Fig. 1, a CONSORT 
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Checklist (27) was also used to standardize reporting; this is shown in Supplemental Digital Content 
1 (Suppl CONSORT Checklist).  
The patients who completed the feasibility study were to be invited to undergo an exact repeat of the 
protocol after approximately 6 months (Part 2 of the study), to collect more pilot data and also start 
assessing potential changes in WGTT due to treatment. Due to project delays and funding timelines 
only 6 patients were able to come back and repeat the protocol. Whilst all 6 additional Part 2 studies 
were completed safely, the numbers are too small for meaningful paired comparison and they are not 
included in this analysis or the results section. 
Study Objectives and Endpoints 
The primary objective of this study was to develop the new device and technique and to assess its 
feasibility on pediatric constipation. The secondary objectives were: (i) to describe WGTT of controls 
and patients. (ii) to describe the safety of the technique. (iii) to describe the effect of the technique on 
Quality of Life (QoL).  
The primary endpoint for feasibility was the number of successful measurements. The secondary 
endpoints were WGTT of controls and patients, the number of Adverse Events (AE) for all 
participants, the change in EQ-VAS scores (young people health on the day) (30) and the baseline EQ-
5D-Y. 
Mini-capsules 
The mini-capsules are classed as an inert marker ingestible medical device (European Union Class IIa) 
designed in partnership with our Young Person Advisory Group (YPAG, see Suppl Text on 
Supplemental Digital Content 2) and manufactured by JEB Technologies Limited (Hampstead 
Avenue, Mildenhall, UK). They enter the body via the oral cavity and travel inside the GI tract where 
they can be located using MRI (in good analogy with X-ray ROMs). The mini-capsules (Fig. 2) were 
made from medical grade polypropylene polymer (8mm×4mm). The shell is invisible to MRI thus the 
mini-capsules were filled with a MRI-visible solution comprising oil and water, with trace amounts 
7 
 
(1µM) of Gadolinium (Gd) contrast agent for increased visibility, and the shell is designed to ensure 
that the contents are  not released in the GI tract. The combination of fat, water and Gd allowed us to 
exploit standard fat and water MRI sequences providing a unique, positive signal, MRI signature for 
the mini-capsules in the large bowel. At the time of the study, the mini-capsules were non-CE marked 
and not FDA approved. They have subsequently been trademarked as TransiCapTM. 
MRI 
A 3T, wide-bore Ingenia scanner (Philips, Best, The Netherlands) was used to acquire MRI. For the 
MRI the participants were not sedated and lay feet first on the scanner bed, in the supine position. A 
3-dimensional 2-echo, mDIXON scan was then acquired to locate the mini-capsules. This provided 4 
image types for each slice acquired: water only, fat only, fat and water in-phase and out-of-phase 
images (31). The liquid filling of the mini-capsules was optimised in conjunction with the imaging 
sequence parameters so that on a derived subtraction of the out-of-phase image from the in-phase 
image the signal of the mini-capsules would be maximised compared to gastrointestinal chime, 
intestinal water and surrounding organs, facilitating their detection. The sequence was acquired both 
in coronal and axial planes, breaking down the 3D volume into stacks of short breath-holds to minimise 
respiratory motion. Five breath holds of 12.3 s each were required to collect the axial image set and 6 
breath holds of 13.5 s were required for the coronal image set. The whole MRI procedure took 
approximately 15-20 minutes. The MRI sequence parameters including length in seconds are provided 
in Supplemental Digital Content 3 (Suppl Table 1). 
Counting of the mini-capsules was performed preferentially on the coronal plane views because the 
anatomy of the colon is simpler to follow in that orientation. If the coronal images were blurred by 
motion or partly obscured by a very full bladder, then the axial images were of additional value for the 
counting. These were observations made at post-processing stage. Four participants had some data sets 
that were more difficult to read because of blurring induced by respiratory motion caused by poor 
breath-holding during some of the imaging image acquisitions but possibly also by gastrointestinal 
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motility due to a recent meal. When blurring was noted by the radiographer at the time of scanning 
some image sets could be repeated immediately, which only required a few additional breath-holds. 
Acquiring both axial and coronal data sets and in separate stacks further helped because if one set was 
found to be blurry a different one could be analyzed. Analysis of one data set took approximately 10 
minutes. 
Data Analysis 
After each scan, the mini-capsules remaining in the gut were located and counted on the derived in-
phase minus out-of-phase images and the WGTT calculated following the Sitzmarks ROM method 
(21). The calculation of WGTT assumes that that by loading the gut with repeated ingestion of the 
mini-capsules over three days, a steady state is reached so that: WGTT in hours = (72 hours / the 
number of mini-capsules ingested over three days) × the total number of mini-capsules remaining in 
the colon. The total number of mini-capsules ingested in this study over 3 days, 72, simplifies the 
multiplying factor so that WGTT = the total number of mini-capsules remaining in the colon at Day 4. 
When some mini-capsules are remaining at Day 7, their contribution to the total transit time is simply 
added to the count at day 4 using the same method. The principle of the WGTT marker method relies 
on loading of the bowel with a plurality of markers not necessarily on their specific total number (9) 
hence the formula above can be adapted in case some of the mini-capsules were mistakenly not 
ingested, by simply changing the denominator for ‘the number of mini-capsules ingested over three 
days’. This happened in one instance in this study leading to one data imputation. All image data were 
analysed by a researcher with MRI radiographer background. The feasibility study was open label and 
they were not blind to which group the patients or controls belonged to, but they did not have 
knowledge of the individual patient histories. All statistical analyses were carried out using Prism 
version 6.07 (Graph Pad Software Inc., La Jolla, CA, USA). Normality of the data was assessed using 
D’Agostino and Pearson test. The comparison of WGTT and EQ-VAS between patients and controls 
was carried out post-hoc. The WGTT data were normally distributed and differences in WGTT 
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between the patients and controls were compared using two-tailed, unpaired t test. The EQ-VAS were 
compared between the baseline time point before the start of the study procedures and the day after 
the study procedures were completed (Day 8). Data were considered significantly different at P < 0.05. 
There was no prior data on the new mini-capsules to estimate sample size and 25 controls as an 
acceptable sample size for a feasibility study (32, 33) and allowing for dropouts. 
 
RESULTS 
Thirty five young persons were studied (Fig. 1). These comprised 16 patients (7 male; 9 female; 
11±3years old; BMI 25±9 kg/m2) and 19 healthy young controls (8 male; 11 female; 16±2years old; 
BMI 25±5 kg/m2). The age between the two groups had a modest but significant difference (Mann 
Whitney P < 0.001) The individual participants’ characteristics are provided in Supplemental Digital 
Content 4 (Suppl Table 2). 
Number of successful measurements and feasibility 
All the 35 participants that ingested the mini-capsules completed the study. Only one of the subjects 
forgot to ingest one of the daily doses and the WGTT calculation was corrected for this. This showed 
very good acceptability of the mini-capsules and MRI procedures. Feedback from the participants and 
the parents, albeit not formally recorded, was positive.  
The mini-capsules were imaged successfully in the colon of all participants using MRI.  
Fig. 4 (a) shows the image of a single coronal image slice clearly showing the mini-capsules with 
bright, positive signal against the darker colon contents of a participant. The image shown in Fig. 4 (b) 
is a projection reconstructed from a multi-slice three-dimensional set of the whole abdomen of another 
participant. The appearance of the markers in the segmented colon here is more similar to X-ray 
imaging with radiopaque markers, an example of which from a different study is shown in Fig. 4 (c) 
for comparison.  
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Whole Gut Transit Time 
From the MRI images, it was possible to count the mini-capsules in the gastrointestinal tract of all the 
participants. The WGTT (Fig. 3), calculated from the mini-capsules count, was 78±35 hours for the 
young patients with constipation, significantly longer than that for the healthy controls 36±16 hours, 
P < 0.0001.  
Number of Adverse events and safety 
There were no Serious Adverse Events (SAEs) in the study. There was only one Adverse Event (AE) 
in the study. This was a single episode of vomiting. It was categorised as mild and quickly resolved, 
requiring no follow up and possibly related to the study procedures.  
The number of mini-capsules detected in the gut decreased with time for all participants. In the patient 
group, the number significantly decreased from 57±11 mini-capsules at day 4 to 19±26 mini-capsules 
at day 7, P = 0.02. For the healthy controls the count significantly decreased from 31±13 at day 4 to 
4±6 at day 7, P < 0.0001.  
Some mini-capsules were present at day 7 in n=11 patients and n=9 healthy controls. These participants 
were recalled for a final scan at day 26-28 post ingestion. No mini-capsules were detected in any of 
the participants at this final time point, thus in part confirming the European Union Class IIa 
classification of the device. 
EQ-VAS scores 
There was no significant difference in EQ-VAS visual analogue scores provided by all participants 
pooled together at baseline before any procedure (87±13) and after completing the mini-capsules and 
MRI intervention at Day 8 (85±18), Wilcoxon’s P = 0.79.  
The young patients’ EQ-VAS grand mean was about 10% lower than for healthy controls with no 
significant differences between groups (P = 0.78). There are also no significant differences in EQ-
VAS scores before and after the mini-capsules and MRI test for patients (Wilcoxon’s P = 0.54) and 
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for healthy controls (Wilcoxon’s P = 0.55). A breakdown of data by patient group is shown in 
Supplemental Digital Content 5 (Suppl Fig 1). 
EQ-5D-Y 
All healthy controls scored their QoL at the lowest score 1 for all dimensions on the EQ-5D-Y 
questionnaires.  Four patients indicated a loss of QoL in the questionnaires. A clerical error prevented 
the administration of the second batch of questionnaires after the MRI study procedures therefore those 
data are not available. 
 
DISCUSSION 
The MAGIC study was a ‘first-in-child’ clinical investigation of a novel medical device. As such we 
set out to assess feasibility, safety and performance of using the new device in the intended population, 
for the intended purpose. The study was successful on various points. 
Assessing feasibility of the new technique was the primary objective of the study. The data showed 
that using the new device and the MRI methods were feasible and the procedures acceptable with 35 
pediatric participants ingesting the mini-capsules and undergoing MRI without refusal and completing 
the study. The intended method to image the mini-capsules, using a derived in-phase minus out-of-
phase fat and water MRI images worked well. The mini-capsules appeared distinctively, with a high 
positive contrast against the colonic chyme. 
Another strength of the whole project was the active participation of children and young persons in the 
co-design of the mini-capsules and of the feasibility study. 
Having imaged the mini-capsules in the colon of these participants we have been able to count them, 
which provided a successful measure of WGTT using the simple algorithm described in the methods. 
Therefore, the new device met the intended purpose of being imaged and identified in the gut, 
monitoring gut transit time using MRI and of measuring the intended WGTT end point of the study in 
pediatric constipated participants and healthy controls. We have also collected a reference mean and a 
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range of whole gut transit time for the healthy controls, which was a secondary objective of the study. 
The new data on mean and standard deviation of WGTT for a reasonable number of pediatric patients 
and controls will also allow us initial inferences on sample size power calculations for future pediatric 
intervention studies.  
When comparing our transit time results with other pediatric data in the literature, Gutierrez et al. (34) 
found transit time in a constipated group of 49.6h versus 29.1 hours in a control non-constipated group. 
They used a radiopaque marker method involving ingestion of 10 markers per day for 6 days followed 
by an X-ray on day 7. Zaslavsky et al. (35) similarly found a transit time of 54.3h in an adolescent 
constipated group versus 30.2 hours in a control non-constipated group, a delay in transit time of 40% 
compared to controls. They used 20 radiopaque markers ingested each day for 3 days followed by an 
X-ray on day 4. The data collected here with our new mini-capsules showed a highly significant 
difference of 54% in whole gut transit time between our young patients with constipation and healthy 
controls. This further corroborates evidence that the new device was able to detect a clinically 
significant difference between pediatric constipation and healthy controls.  
In this study we measured WGTT by counting the number of capsules remaining in the bowel at 
predetermined time points. Measuring segmental transit times in different tract of the colon was not 
an outcome for this study. Segmental transit times were once more popular particularly to inform 
segmental surgical resection but recently controversy has been reported about this treatment and its 
uncertain benefits (36, 37). The cross-sectional quality of MRI can provide an advantage over X-ray 
to assign the location of markers as bowel loops can overlap in the two-dimensional X-ray abdominal 
film, thought this needs to be assessed formally.  
The study had a very good safety record. There was only one episode of vomit categorised as an 
adverse event. It is worth noting that this participant continued the study, completed the rest of the 
procedures and agreed to come back for one of the Part 2 studies which they completed successfully, 
further illustrating the mild nature of that adverse event.  
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The EQ-VAS scores showed no difference before and after the study procedures indicating that 
undergoing the study and the procedures did not alter the score of the patients and of the healthy 
participants. 
The study had some limitations. The baseline EQ-5D-Y for the participants were not repeated after the 
study due to a clerical error thus preventing an appropriate assessment of changes in QoL.  
The patient participants reached the specialist clinics in the hospital as they required expertise more 
than that available within primary and secondary care. Our pool included also those referred from other 
community paediatric clinics and general paediatric clinics within the region. As such, they were at 
various stages of treatment, when they participated in the study. There was no expectation that patients 
would change treatment plan whilst being investigated. It is interesting that despite this and their 
heterogeneity we demonstrated a longer WGTT in the patient group. At the same time this did not 
allow us to collect meaningful data on changes in gut transit upon treatment. The original design 
included an invitation to all patients to come back to repeat the feasibility study as a ‘Part 2’ 
approximately 6 months after the first participation. Due to delays in recruitment and funding 
timelines, and also some difficulty in communicating with the satellite district hospitals and 
practitioners, we were able to re-test only 6 patients. They all repeated the MRI study safely, but the 
sample is too small to provide meaningful comparisons and these repeated data were excluded from 
the analysis. There was a significant difference in age between the two groups though this was modest 
and did not seem to affect this feasibility study. 
Some of the youngest participants reported feeling nervous at the start of the study, which is 
understandable for people who had not previously participated in a clinical investigation or had an 
MRI scan, but this did not stop any of them participating and they quickly relaxed and came back very 
happily for all the other visits. A further limitation of this study is that we did not set out to collect 
formal questionnaire feedback on how the procedures were perceived, the burden of attending and of 
going in the MRI scanner. A few data sets were blurred by motion. An observation made at post-
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processing was that the large region of high intensity signal from a full bladder may make mini-capsule 
detection more difficult, particularly in the distal colon / rectum area, on the coronal image plane 
orientation although further post-processing techniques could overcome some difficulties. We also 
noted that participants who came in having just recently eaten a large breakfast or meal showed higher 
stomach and small bowel motility, which can also blur some image sets, particularly in the upper 
abdomen. Possible suggestions for improvement for the future could include more detailed 
explanations of the breath-holding and training young participants to hold their breath before the MRI 
scans, and recommending emptying of the bladder before going in the MRI scanner and a couple of 
hours of fasting before the MRI test. Clearly the utility of this mode of investigation is one to evaluate 
further. Constipation is a very common problem and whilst the vast majority of children and young 
persons will respond to simple treatment with stool softeners and bowel stimulant, there is a significant 
proportion of patients who do not show signs of improvement despite follow up. It is important to in 
these cases to evaluate the WGTT in order then to individualise therapy.  
A non-contrast pediatric MRI scan to a single area of the body cost more than an X-ray (in the UK 
health system about 4 times more) so MRI cost and availability are issues to be taken into account. In 
the pediatric population, avoiding ionizing radiation exposure is a definite advantage of the new 
technique that should counterbalance the economic argument. The additional cross sectional imaging 
additional information on the bowel anatomy that can be gathered within the same scan is also an 
advantage of MRI. In terms of availability, it is true that MRI units are particularly busy with clinical 
routine. However, when new bowel imaging scans prove their worth they enter that clinical routine as 
it happened for MRI cholangiopancreatography and MRI enterography. 
Here the primary aim of the study was simply to evaluate the feasibility of this test in children being 
looked after in a typical clinic set up. A full health economics evaluation needs to follow to evaluate 
the cost benefit analysis, taking into account not only the total duration of treatment and continued 
follow up within a paediatric clinic but also school days lost because of faecal incontinence, and the 
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impact of productivity for carers as they take time off to look after children with chronic constipation 
with overflow. The X-ray ROM protocol that we have copied for this initial study (3 daily doses of 24 
markers) is a common one but it is not necessarily the only one used in past literature. The new MRI 
mini-capsules could be used in the future with other imaging protocols such as a single dose, single 
imaging time point (9) and also in adults, though further investigation and validation will be needed. 
A new multi-centre study of the mini-capsules in pediatric constipation was funded and is under way 
(Trial ID: ISRCTN42273449). 
 
CONCLUSIONS 
MAGIC was a first-in-child feasibility study of the new mini-capsule medical device (TransiCapTM) 
to measure whole gut transit time in pediatric constipation using MRI. The study showed that the 
device met safety and performance objectives as per the intended purpose, with excellent feasibility 
and safety of using the new device in conjunction with MRI. The new device may represent a modern 
alternative to current X-ray ROM methods whilst not exposing the young patients to any ionizing 
radiation and at the same time providing high quality cross sectional images of the bowel. The clinical 
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FIGURES AND SUPPLEMENTARY MATERIAL LEGENDS 
 
Figure 1. CONSORT diagram for the study. 
 
Figure 2. Mini-capsule MRI device markers pictured near a 20 pence coin (21 mm in diameter) for 
size comparison. 
 
Figure 3. Whole gut transit time (mean and SD) for young patients with constipation (n=16) and 
healthy controls (n=19). * P < 0.0001. 
 
 
Figure 4. (A) A coronal, derived in-phase minus out-of-phase MRI image of a 7 year old patient 
participant, showing in the sigmoid/rectum 6 mini-capsules with positive signal against the chime. The 
mini-capsules are indicated by the white arrows in the corresponding expanded area on the right hand 
side. (B) An axial, derived in-phase minus out-of-phase MRI image of the same patient participant, 
showing in the descending colon 2 mini-capsules with positive signal against the chyme. The mini-
capsules are indicated by the white arrows in the corresponding expanded area on the right hand side. 
 
Supplemental Digital Content 1 – Suppl CONSORT checklist. CONSORT checklist of reported 
trial information.  
 






Supplemental Digital Content 3 – Suppl Table 1. MRI sequence parameters.  
 
Supplemental Digital Content 4 – Suppl Table 2. Individual participants’ characteristics.  
 
Supplemental Digital Content 5 – Suppl Figure 1. Young participants’ EQ-VAS scores before and 
after undergoing the mini-capsules ingestion and MRI scan procedures. The values shown are 
mean±standard deviation. Wilcoxon’s P = 0.54 the patients and P = 0.55 for the healthy controls 
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Supplemental Digital Content 1: CONSORT checklist 
 




No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title Not applicable 




2a Scientific background and explanation of rationale 3-4 
2b Specific objectives or hypotheses 4, 6 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5-6 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Not applicable 
Participants 4a Eligibility criteria for participants 4-5 
4b Settings and locations where the data were collected 4 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
5-6 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
6 
6b Any changes to trial outcomes after the trial commenced, with reasons 11 
Sample size 7a How sample size was determined Not applicable 
7b When applicable, explanation of any interim analyses and stopping guidelines Not applicable 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence Not applicable 
8b Type of randomisation; details of any restriction (such as blocking and block size) Not applicable 
 Allocation 
concealment 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
Not applicable 
CONSORT 2010 checklist  Page 2 
mechanism 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
Not applicable 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
Not applicable 
11b If relevant, description of the similarity of interventions Not applicable 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 8-9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 8-9 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
Figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons Figure 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 4 
14b Why the trial ended or was stopped Not applicable 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 9, Suppl 
Table 2 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 




17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
9-11 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Not applicable 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
9-11 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Not applicable 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 13-14 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 14-15 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 11-13 
Other information  
Registration 23 Registration number and name of trial registry 5 
Protocol 24 Where the full trial protocol can be accessed, if available Not applicable 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Title page 
CONSORT 2010 checklist  Page 3 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
 
 
Supplemental Digital Content 2: Supplemental Text 
Patient and Public Involvement and Engagement 
 
The patient and public involvement and engagement (PPI/E) in this project was recurrent and meaningful since 
inception. We co-designed and co-produced the TransicapTM mini-capsules and the packaging, with the Young 
Person Advisory Group (YPAG) working in person with the designers at Renfrew Group International (Abbey 
Meadows, Leicester, UK) and the technology consultants from the NIHR from the Enteric Health Technology 
Cooperative. Together with the YPAG members we designed the MAGIC project website 
www.gastrointestinalmri.org.uk, we scripted, produced and narrated two novel, animated pediatric video info 
sheets, now Ethics approved and on YouTube https://youtu.be/luvIutiTvr4 and https://youtu.be/w5O8lhZqEs8.  
 
We wrote age-appropriate Ethics information sheets (praised by the Ethics Committee) and presented together 
at the podium of the Nottingham Pediatric Research Showcase 2018 (winning 2nd best oral presentation) and at 
the UK Clinical Research Facilities conference 2019. 
We continue working with the YPAG and some of their comments on the progress of the co-production can be 





Supplemental Digital Content 3: Table 1 
 
 
SUPPLEMENTAL TABLE 1. MRI sequence parameters  
MRI sequence 3D T1 weighted TFE * 
Image orientation Axial Coronal 
Field of View 350 mm (RL) × 280 mm (AP) 348 mm (RL) × 250 mm (HF) 
Image stacks † 5 ‡ 6 § 
Slices per stack 33 27 
Length of breath hold per stack 12.3 s 13.5 s 
SENSE acceleration factor 2 2 
Signal averaging 1 1 
Flip angle 20° 20° 
Repetition time TR 10 ms 10 ms 
Echo times TE1 / TE2 1.32ms / 2.2 ms 1.32ms / 2.2 ms 
Reconstruction matrix 400 × 400 400 × 400 
Acquired image resolution 1.8 mm × 1.8 mm × 4.4 mm 1.8 mm × 1.8 mm × 4.4 mm 
Reconstructed image resolution 0.88 mm × 0.88 mm × 2.2 mm 0.87 mm × 0.87 mm × 2.2 mm 
 
* mDIXON sequence on Philips MRI scanner used 
† The image stacks (packages) were acquired with no gaps between them, reconstructed independently and 
then put back together as a full section.  
‡ The scanner table moved between each stack 
§ The scanner table moved between a 'top' and a 'bottom' sections and then 3 stacks were acquired at each of 









SUPPLEMENTAL TABLE 2. Individual participants’ characteristics 
Participant 
number  
Patient or healthy 
control 






1 Healthy control 16 Female 63 1.65 23.0 
2 Healthy control 17 Female 65 1.63 24.5 
3 Patient 8 Male 60 1.30 35.5 
4 Healthy control 11 Male 48  1.60  18.7 
5 Healthy control 14 Male 52 1.60 20.3 
6 Healthy control 16 Female 63 1.70 21.8 
7 Patient 11 Male 99 1.67 35.5 
8 Healthy control 17 Male 72 1.79 22.5 
9 Healthy control 17 Female 70 1.70 24.2 
10 Healthy control 15 Female 58 1.59 22.8 
11 Patient 10 Female 41 1.05 37.1 
12 Healthy control 18 Male 85 1.69 29.8 
13 Healthy control 18 Male 91 1.75 29.7 
14 Healthy control 17 Male 70 1.73 23.4 
15 Healthy control 18 Male 106 1.67 38.0 
16 Healthy control 16 Female 59 1.71 20.2 
17 Patient 13 Female 60 1.64 22.3 
18 Patient 7 Male 25 1.28 15.5 
19 Healthy control 14 Female  55 1.60   21.4 
20 Patient 8 Female 48 1.30  28.4  
21 Healthy control 17 Female 57 1.52 24.7 
22 Healthy control 17 Male 80 1.85 23.4 
23 Healthy control 15 Female 97 1.79 30.3 
24 Healthy control 18 Female 57 1.63 21.5 
25 Patient 10 Male 34  1.20  23.6 
26 Patient 16 Female 68 1.55 28.3 
27 Patient 10 Female 22 1.28 13.2 
28 Patient 12 Male 34 1.40 17.3 
29 Patient 9 Female 35  1.20 24.3  
30 Patient 18 Female 52 1.25 33.3 
31 Patient 13 Male 60 1.54 25.3 
32 Patient 13 Male 42 1.54 17.7 
33 Patient 14 Female 63 1.64 23.4 
34 Patient 7 Female 23 1.20 15.9  
35 Healthy control 10 Female 42 1.45 20.0 
 
